摘要
中心性浆液性脉络膜视网膜病变(CSC)是临床中常见的黄斑病变,可使年轻患者的中心视力下降。该病虽具有一定自限性,但临床中不乏病程迁延、反复发作的患者,最终导致视力不可逆损伤。因此,在一定时期采取合理的治疗手段对患者的视力预后尤为重要。通过热激光光凝渗漏点和光动力疗法(PDT)虽取得不错疗效,但存在视网膜损伤、视网膜色素上皮萎缩等风险。阈值下微脉冲激光(SMLP)是一种阈值下短脉冲激光,不会对视网膜造成可见损伤,安全性更高。在PDT药物乏的时代,SMLP逐渐成为CSC临床治疗的重要手段,尤其适用于无明显渗漏点或中心凹下渗漏点的患者。深入了解SMLP的作用机制、治疗CSC的疗效和安全性,有助于SMLP在CSC临床治疗中的推广和应用。
Central serous chorioretinopathy(CSC)is a common macular disease,which can lead to the loss of central vision in young patients.Although the disease is self-limited to some extent,there is no shortage of patients with prolonged course and recurrent attacks,eventually leading to irreversible visual impairment.Therefore,taking reasonable treatment in a certain period is particularly important for the visual prognosis of patients.Although thermal laser photocoagulation of leakage points and photodynamic therapy(PDT)have achieved good effects,there are risks of retinal damage and retinal pigment epithelium atrophy.Subthreshold micropulse laser(SMLP)is a kind of subthreshold short pulse laser,which does not cause visible damage to the retina and is safer.In the era of lack of PDT drugs,SMLP has gradually become an important means of clinical treatment for CSC,especially for patients with no obvious leakage point or subfoveal leakage point.An in-depth understanding of the mechanism of action of SMLP and its efficacy and safety in the treatment of CSC is helpful for the promotion and application of SMLP in the clinical treatment of CSC.
作者
齐元
刘丽娅
马菲妍
尚庆丽
Qi Yuan;Liu Liya;Ma Feiyan;Shang Qingli(Department of Ophthalmology,Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2023年第4期337-340,共4页
Chinese Journal of Ocular Fundus Diseases
基金
河北省医学科学研究课题计划项目(20211081)。
作者简介
通信作者:刘丽娅,Email:liuliya81@sina.com。
